Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 4:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Edema Arm Clear all
Completed Phase 3 Interventional Results available

The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study

NCT00105027
View directory record Official record
Conditions
Macular Edema, Cystoid, Retinal Vein Occlusion
Interventions
Standard Care, intravitreal triamcinolone injection
Other · Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 15, 2026, 4:49 AM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

NCT03810313
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 15, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT04740905
View directory record Official record
Conditions
Macular Edema, Branch Retinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 15, 2026, 4:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Wireless TENS for Peripheral Edema (Lower Limb Swelling)

NCT04680533
View directory record Official record
Conditions
Peripheral Edema
Interventions
Transcutaneous Electrical Nerve Stimulation (TENS)
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 15, 2026, 4:49 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

NCT04603937
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
40
States / cities
Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 15, 2026, 4:49 AM EDT
Active, not recruiting No phase listed Observational

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05476926
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Interventions
Faricimab, Port Delivery System with Ranibizumab
Drug · Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Pasadena, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 15, 2026, 4:49 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

NCT01011374
View directory record Official record
Conditions
Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
Interventions
ranibizumab (Lucentis)
Drug
Lead sponsor
Retina Associates of Cleveland, Inc
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2011 · Synced Sep 15, 2026, 4:49 AM EDT
Recruiting No phase listed Observational

Screening For BCRL In Targeted Therapy For Breast Cancer

NCT05142800
View directory record Official record
Conditions
Lymphedema, Lymphedema Arm, Lymphedema of Upper Arm, Lymphedema of Upper Limb, Lymphedema of the Hands, Edema, Edema Arm, Breast Cancer Lymphedema, Breast Cancer Metastatic, Breast Cancer Stage, Breast Cancer
Interventions
Perometer, SOZO device
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 15, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03481634
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Brolucizumab, Aflibercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 15, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT01521559
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Procedure · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Sep 15, 2026, 4:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Ranibizumab for Diabetic Macular Edema

NCT01982435
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Justis Ehlers
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Cleveland, Ohio • Mayfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 15, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab

NCT04597918
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Faricimab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Naples, Florida • Chicago, Illinois • Oak Forest, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 15, 2026, 4:49 AM EDT
Not listed Phase 1 Interventional

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120636
View directory record Official record
Conditions
Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Celecoxib
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Sep 15, 2026, 4:49 AM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT03802630
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 15, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion

NCT01198327
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
ranibizumab, Peripheral Laser
Drug · Other
Lead sponsor
Peter A Campochiaro, MD
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Beverly Hills, California • Sacremento, California • Augusta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 15, 2026, 4:49 AM EDT
Active, not recruiting Phase 4 Interventional

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

NCT05224102
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Faricimab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Arcadia, California • Campbell, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 15, 2026, 4:49 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

NCT00406107
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
pegaptanib sodium (Macugen)
Drug
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Los Angeles, California • Hagerstown, Maryland • West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Sep 15, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)

NCT05712720
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402, Placebo: Group 4 - Placebo
Drug · Other
Lead sponsor
Rezolute
Other
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 15, 2026, 4:49 AM EDT
Recruiting Not applicable Interventional

LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)

NCT04606030
View directory record Official record
Conditions
Lymphedema, Edema
Interventions
BioBridge® Collagen Matrix, Vascularized Lymph Node Transfer (VLNT)
Device · Procedure
Lead sponsor
Fibralign Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 15, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

NCT02698566
View directory record Official record
Conditions
Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Paducah, Kentucky • Charlotte, North Carolina • Chattanooga, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Sep 15, 2026, 4:49 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

NCT05127525
View directory record Official record
Conditions
Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
Interventions
IRX-101, Control
Drug
Lead sponsor
iRenix Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 15, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe

NCT05569148
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions
Faricimab PFS Configuration
Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Mesa, Arizona • Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 15, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT04592419
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
81
States / cities
Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 15, 2026, 4:49 AM EDT
Not listed Phase 1 Interventional

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120311
View directory record Official record
Conditions
Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Dexamethasone
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Sep 15, 2026, 4:49 AM EDT